It is understood that China’s instrumentation industry, driven by scientific and technological progress and vigorous industrial development, has entered a new era of trillion yuan scale. However, in 2023, the development of enterprises in the industry shows a significant polarization phenomenon, the overall profit performance is poor, at the same time of rapid growth, instrumentation companies are also facing the major challenges of industrial upgrading and transformation. As 2024 gradually enters the summer season, domestic listed instrument companies have disclosed the 2023 annual report, and their business performance has become the focus of attention in the industry. The instrument Information network takes more than 40 listed instrument companies in China as the research object, and lists the top 40 net profits attributable to shareholders of listed companies in 2023 according to their published financial data.

330104-00-03-90-02-05 Note: Since the opening of the market on April 4, 2023, the stock abbreviation of *ST Kehua Company will be changed from “*ST Kehua” to “Kehua Biology”, and the stock code will remain “002022”, *ST Kehua will become the first listed company to “take off the star and take off the hat” in 2023 on the Shenzhen Stock Exchange.

As can be seen from the figure, among the 42 listed enterprises, 31 enterprises have positive net profit, the highest is Mindray Medical, reaching 11.582 billion yuan, an increase of 20.56%, which is nearly 10 times that of the second Antu Biological, 1.217 billion yuan. The net profit of 11 enterprises was negative, and the lowest was Huada Intelligent Manufacturing, whose net profit was -607 million yuan, down 129.98% year-on-year.

Mindray Medical net profit exceeded 10 billion

In 2023, Mindray Medical’s net profit to the mother exceeded 10 billion for the first time. It is understood that Mindray Medical’s net profit to the mother has maintained a growth rate of more than 20% for six consecutive years since its listing, and the compound growth rate of net profit has reached 25.51% in five years. According to the quarterly report released by Mindray Medical in 2024, the company’s revenue was 9.373 billion yuan, an increase of 12.06%, and its net profit was 3.160 billion yuan, an increase of 22.90%, and the performance trend continued to be good. In addition, Mindray Medical in vitro diagnostic instruments and equipment achieved outstanding installed performance during the reporting period, including more than 2,000 BC-7500 series installed.

330104-00-03-90-02-05 The extension merger and acquisition has always been one of the foothold of Mindray Medical’s performance growth. Since setting out on the road of global mergers and acquisitions in 2008, a number of domestic and foreign mergers and acquisitions have greatly improved Mindray’s core technology, marketing platform and supply chain platform, as well as new business expansion. During the reporting period, the integration of the company and the research and development team of Sea peptide biology progressed smoothly, and the new research and development projects of sea peptide biology have been integrated into the overall management of the company’s in vitro diagnosis business; The Company completed the acquisition of 75% of DiaSys Diagnostic Systems GmbH for cash, and DiaSys officially became a majority-owned subsidiary of Mindray. At the same time, in January 2024, Mindray Medical announced the acquisition of A-share listed company Huitai Medical, becoming the largest shareholder and controlling shareholder of Huitai Medical, and cardiovascular business will also be one of the key areas of the company’s next efforts.